📰 Cheaper Wegovy and an FDA approval for Novo Nordisk
A great week for the Danish Pharamaceutical
Two big pieces of news have been floating around this week:
MASH (“fatty liver”) FDA approval for Semaglutide (Wegovy)
Partnership with GoodRx to provide $499 Wegovy & Ozempic
Both of these are great news for Novo Nordisk and the GLP1 ecosystem on the whole — we took a look at the most important takeaways.